We are pleased that the FDA has accepted our submission and look forward to working with regulatory authorities on what would be the first oral GLP-1 treatment for obesity." References FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity
Most people experience initial appetite suppression within 37 days of their first injection, though the timeline and intensity vary based on individual biology
GLP-1 has truly transformed my approach to weight management, and Im finally seeing the results Ive always hoped for! After giving birth at the age of 40, I struggled to lose the excess weight
The balance of available evidence through clinical trials and surveillance indicates that severe skin reactions are uncommon, but they do occur and deserve careful attention
These are the key messages that translate InBody results into actionable, motivating guidance for patients on semaglutide therapy